Skip to main content

Advertisement

ADVERTISEMENT

News

News
11/15/2022
On November 14, 2022, the FDA approved mirvetuximab soravtansine-gynx, administered intravenously every 3 weeks, for adult patients with folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal...
On November 14, 2022, the FDA approved mirvetuximab soravtansine-gynx, administered intravenously every 3 weeks, for adult patients with folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal...
On November 14, 2022, the FDA...
11/15/2022
Oncology
News
10/27/2022
Study findings show apatinib plus pegylated liposomal doxorubicin yields promising results in efficacy and safety among patients with platinum-resistant ovarian cancer.
Study findings show apatinib plus pegylated liposomal doxorubicin yields promising results in efficacy and safety among patients with platinum-resistant ovarian cancer.
Study findings show apatinib...
10/27/2022
Oncology
News
09/19/2022
Findings from a phase 3 study confirm the safety and efficacy of pafolacianine injection for real-time detection of folate receptor-positive ovarian cancer.
Findings from a phase 3 study confirm the safety and efficacy of pafolacianine injection for real-time detection of folate receptor-positive ovarian cancer.
Findings from a phase 3 study...
09/19/2022
Oncology

Advertisement

Conference Coverage
09/09/2022
In the final overall survival analysis of a phase 3 trial, olaparib plus bevacizumab was found to meaningfully improve overall survival for patients with advanced ovarian cancer and homologous recombination deficiency, with or without tumor...
In the final overall survival analysis of a phase 3 trial, olaparib plus bevacizumab was found to meaningfully improve overall survival for patients with advanced ovarian cancer and homologous recombination deficiency, with or without tumor...
In the final overall survival...
09/09/2022
Oncology
Conference Coverage
09/09/2022
The ATALANTE trial evaluating the addition of atezolizumab to platinum-based chemotherapy plus bevacizumab for platinum-sensitive ovarian cancer failed to meet its coprimary PFS end points, according to data presented at the 2022 ESMO...
The ATALANTE trial evaluating the addition of atezolizumab to platinum-based chemotherapy plus bevacizumab for platinum-sensitive ovarian cancer failed to meet its coprimary PFS end points, according to data presented at the 2022 ESMO...
The ATALANTE trial evaluating...
09/09/2022
Oncology
News
07/28/2022
Determining p53 status by IHC can help select the patients with endometrial cancer most likely to experience survival benefit when treated with bevacizumab plus chemotherapy, according to a phase 2 study.
Determining p53 status by IHC can help select the patients with endometrial cancer most likely to experience survival benefit when treated with bevacizumab plus chemotherapy, according to a phase 2 study.
Determining p53 status by IHC...
07/28/2022
Oncology

Advertisement

News
07/05/2022
First-line weekly chemotherapy showed no improvement in PFS or OS compared to chemotherapy administered every 3 weeks among patients with epithelial ovarian cancer, according to a phase 3 trial.
First-line weekly chemotherapy showed no improvement in PFS or OS compared to chemotherapy administered every 3 weeks among patients with epithelial ovarian cancer, according to a phase 3 trial.
First-line weekly chemotherapy...
07/05/2022
Oncology
News
07/05/2022
Olaparib dose reduction and interruption for the management of olaparib-related adverse events show no impact on survival in patients with BRCA-mutated ovarian cancer, according to a recent study.
Olaparib dose reduction and interruption for the management of olaparib-related adverse events show no impact on survival in patients with BRCA-mutated ovarian cancer, according to a recent study.
Olaparib dose reduction and...
07/05/2022
Oncology
Conference Coverage
06/06/2022
Single-agent trabectedin was not associated with improved survival outcomes compared to standard chemotherapy for patients with BRCA–positive ovarian cancer, according to results from a phase 3 trial.
Single-agent trabectedin was not associated with improved survival outcomes compared to standard chemotherapy for patients with BRCA–positive ovarian cancer, according to results from a phase 3 trial.
Single-agent trabectedin was not...
06/06/2022
Oncology

Advertisement

Conference Coverage
06/06/2022
Rucaparib monotherapy provides significant benefit over placebo as first-line maintenance treatment following platinum-based chemotherapy in ovarian cancer, according to results from the ATHENA-MONO trial.
Rucaparib monotherapy provides significant benefit over placebo as first-line maintenance treatment following platinum-based chemotherapy in ovarian cancer, according to results from the ATHENA-MONO trial.
Rucaparib monotherapy provides...
06/06/2022
Oncology

Advertisement